A novel therapeutic diet can significantly reduce the medication score and pruritus of dogs with atopic dermatitis during a nine-month controlled study

Adrian Watson*†, Ana Rostaher†, Nina M Fischer† and Claude Favrot†

*Royal Canin SAS, Aimargues, France
†Clinic for Small Animal Internal Medicine, Vetsuisse Faculty University of Zurich, Winterthurerstrasse 260, Zurich, 8057, Switzerland
Correspondence: Adrian Watson, Royal Canin SAS - Research and Development, 650 Avenue de la Petite Camargue Aimargues, Gard 30470, France. E-mail: adrian.watson@effem.com

Background – Canine atopic dermatitis (cAD) is a common chronic relapsing pruritic skin disease for which management commonly relies on life-long use of immunomodulatory drugs. A number of the medications used are associated with adverse effects and the potential for complications during long-term use.

Hypothesis – The goal of the study was to determine if a complete and balanced diet formulated for therapeutic benefit could contribute towards management of cAD. We hypothesised that the diet would reduce pruritus while also reducing the requirement for medication during the study period.

Animals, materials and methods – Forty privately owned dogs, having undergone a comprehensive diagnosis for cAD, were randomly allocated to two groups, each group being fed one of two diets (test or control) for up to nine months. We assessed pruritus, Canine Atopic Dermatitis Extent and Severity Index-(4th iteration) and medication score, the latter reflecting the medication required to maintain a satisfactory quality of life for the animal.

Results – Both diets were well-accepted and -tolerated. There was a significant improvement in the pruritus score after three months of feeding the therapeutic diet (P = 0.0001). No such improvement was observed at any time point in the control group. We assessed pruritus, Canine Atopic Dermatitis Extent and Severity Index-(4th iteration) and medication score, the latter reflecting the medication required to maintain a satisfactory quality of life for the animal.

Conclusion – The results suggest that a novel therapeutic diet can assist in the management of cAD by helping to control pruritus and reducing reliance on medication.

Introduction

Canine atopic dermatitis (cAD) is a multifactorial disease associated with immunological dysregulation and skin barrier abnormalities. Treatment is based mainly on the use of anti-inflammatory and/or immunomodulatory drugs, while the use of epidermal barrier treatments is mainly considered supportive. Immunomodulatory drugs unfortunately may be associated with detrimental adverse effects. It is well-known that dietary components or additives may positively influence the course of human atopic dermatitis (AD). The influence of these phytochemicals on allergic reactions has been studied in some detail and potential efficacy is established. In veterinary medicine, the role of essential fatty acids and some anti-oxidants has been assessed. Dietary supplements often are advocated for mild to moderate atopic disease as part of a multimodal approach, and some studies have shown a benefit. However, administration increases the burden of treatment, requiring dosing at minimum once per day. Therefore, incorporation of helpful ingredients into a complete meal format can add to convenience, with the potential to see concomitant improvements in compliance. What is more, it has been illustrated that food-integrated nutrients are more effective than supplements. While some diets have been developed for the management of AD in dogs, well-controlled studies are still lacking.

The goal of this study was to assess the clinical efficacy of a diet specifically developed to target the pathological mechanism of cAD to assist in the long-term management of this condition.

Methods and materials

Owner consent, Ethics and General Data Protection Regulation (GDPR) statement

The protocol was approved by the local Kanton Zurich ethical committee (ZH114/18) as well as the Royal Canin Ethical Research Committee. An informed consent form was signed by all dog owners who participated. Any personal data relating to participants in the study was the minimum required and was held only for as long as needed to execute the study, according to GDPR.

Dogs

Privately owned atopic dogs with nonseasonal pruritus were included. All dogs were treated in private practice clinics. The acceptance date, source of funding, conflicts of interest, and ethical statement are provided for the study.
diagnosis of AD was made using standard criteria, after exclusion of ectoparasites and other complicating diseases such as bacterial and yeast infections.12 Dogs with active bacterial and/or yeast infections, as well as individuals responding adequately to an eight weeks elimination diet and re-challenge with previous diet, namely, dogs classified as food allergic were not included. Moreover, dogs with ongoing allergen-specific immunotherapy for <12 months or dogs controlled with this intervention alone were not enrolled. Included dogs needed to be receiving ongoing ectoparasite treatment and this treatment was continued throughout the study. Concomitant medications (see Appendix 1 for list), excluding all nutritional supplements, were allowed throughout the study to comply with ethics and ensure an optimal quality of life (QoL), and were carefully recorded throughout.

Inclusion consultation and initial clinical scoring
All enrolment and clinical evaluations were performed by qualified and experienced veterinary dermatologists. Included dogs were initially evaluated for skin lesions and pruritus using Canine Allergic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and Hill’s pruritus Visual Analog Score (pVAS), respectively.11 Medications used during the month before inclusion were recorded. A medication score was made as published previously.12 Briefly, as depicted in Table 1, monthly treatments were recorded, with the specific drug, dose and frequency of use being attributed a numerical score. The overall score for each month was determined by summation daily scores. The figures reported for medication score are the monthly totals divided by the number of days in the month, thereby providing a daily average.

Follow-up consultations and drop-out
Follow-up consultations were made after one month (phone call), three, six and, when possible, nine months. The one month consultation was aimed at recording any problems associated with the study, for example diet palatability, in addition to recording the medication and pruritus scores. Consultations after three, six and nine months consisted of general examination of the dogs, CADESI-04, pVAS and medication score. At each time point the consumption of the diets was reported by the owners using a binary yes/no question with comments if needed. In addition, throughout the study owners were asked to evaluate the quality of the dogs’ stools in order to assess how well the diet was being tolerated. Stool quality was assessed according to a five-point scale, illustrated by picture (grade 5; hard; 4, well-formed, easy to pick up; 3, well-formed but soft; 2, very wet but not liquid; and 1, liquid diarrhoea).

Owners were permitted to withdraw their dogs from the study at any time and for any reason. They were encouraged to feed their dogs exclusively with the diet provided for at least three months. In the event of a dog being withdrawn, owners who were not satisfied with the efficacy of the diet were given the opportunity to swap to the test diet for the remainder of the study period. In this case the diet provided was renamed (code Pebble) to maintain blinding. Drop-out reasons were recorded. Dogs maintained on any of the diets for a minimum of three months were considered for statistical analyses.

Diets
The study was double-blinded and placebo-controlled. Enrolled dogs were randomly allocated into one of the two study groups. One group of dogs received the test diet (code Flame) while the other group received a standard premium diet (placebo: code Ice). Both of the diets contained chicken as the protein source and were produced at a commercial manufacturing facility in France. The diets were dry kibble format (Figure 1), and were complete and balanced for dogs at maintenance energy requirement (95 kcal/kg0.75 NRC 2006).13 A comparison of the key nutritional components of the two diets can be found in Table 2. The diets were packaged in identical neutral bags, differentiated only by their code names. Both diets were composed of standard pet food materials, the test diet was supplemented with turmeric and licorice extracts. The turmeric extract (Curcuma longa) was provided by Arjuna (Kerala, India) and contained 95% curcuminoids with enhanced bioavailability. The licorice extract (Glycyrrhiza glabra), supplied by Naturex (Avignon, France) was prepared from the root of the plant. The extract was standardised for glycyrrhizin concentration (12% w/w). The concentration of the omega-6 fatty acid linoleic acid in the Flame diet was increased by replacing a proportion of poultry and pork fat in the Ice diet with soya oil and fish oil. The omega-3 fatty acids were supplemented using the fish oil. As stated previously, neither the owners nor the investigators were informed as to the nature of the diet. Owners were instructed to feed only the study diets provided for the entirety of the study. When dogs were transitioning from their previous diet to the study diets, owners were advised to change gradually over six days (two days each of 75%:25%, 50%:50%, 25%:75%).

Outcome measures
Drop-out reasons and unexpected events were recorded. The percentages of dogs with >30% and >50% improvement of the clinical score were computed for both groups. Additionally, the number of dogs returning to normal (CADESI-04 < 16, pVAS < 2.5 and medication score < 10) were recorded in both groups.

Statistical methods
Statistical analyses were performed using JMP® v14 (Cary, NC, USA). Linear mixed models were used for evaluating the impact of diet, time and time-by-diet interactions on CADESI-04, pVAS and medication score. Animal was modelled as random term.

Log-transformation was used when necessary to meet the statistical assumptions of a linear mixed model (normally distributed residuals and homoscedasticity). Tukey’s honestly significant difference (HSD) was used for the post hoc multiple comparisons. Level of significance was set at 5%. Medians (min–max) were provided for the studied parameters.

Results
Study population detail
Forty dogs were initially included and allocated to one of the two study groups, one to be fed the test diet Flame (n = 21) and the other to be fed the placebo diet Ice (n = 19). The male:female ratio was 21:19 and the mean age was 5.2 years (SD ±1.78). No age or sex difference
was found between groups. Some breeds were over-
represented, in particular French bulldogs (n = 11), West
Highland white terriers (n = 3), Labrador retrievers (n = 3)
and American Staffordshire terriers (n = 3). Multiple dogs
of the same breed were present in both groups.

At inclusion, the median CADESI-04 scores in the
Flame and Ice groups were 19 (11–59) and 18 (6–69),
respectively. The median pruritus scores were 5.5 (2.8–
6.8) and 4.6 (3–8.5) respectively. The medication scores
were 20 (10–45) and 30 (5–60), respectively. There was
no significant difference between the two diet groups for dropout
frequency (P = 0.75).

Table 2. Concentrations of key nutritional components of the two
diets fed during the study. Details of the diets are given for the prox-
mates and a group of other ingredients which differed significantly
between the Test (Flame) and Control (Ice) diets

| Units | Flame | Ice |
|-------|-------|-----|
| Dry matter % | 90.50 | 90.51 |
| Moisture % | 9.50 | 9.49 |
| Protein % | 22.54 | 22.51 |
| Fat % | 13.97 | 13.99 |
| Ash % | 6.90 | 6.89 |
| CFIB (crude fibre) % | 2.90 | 2.90 |
| Linoleic acid % | 3.90 | 2.20 |
| EPA+DHA % | 0.54 | 0.01 |
| Vitamin E mg/kg | 900.64 | 162.14 |
| Taurine mg/kg | 4500 | 600 |
| Lutein mg/kg | 5 | 0.74 |
| Curcuma extract mg/kg | 300 | 0 |
| Licorice root extract mg/kg | 200 | 0 |

EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

Score comparisons

Pruritus (pVAS)

There was clear evidence of an improvement in the pruri-
tus score for the Flame diet group after three months
compared to the start of the study, the median score
decreasing from a baseline value of 5.5 to 3.0 (ranges 3–7.6
at baseline and 0–6 at three months; P = 0.0001). There
was no significant difference between pVAS within the Flame
group between 0 and six months (median 4.35 to
2.13), but the score reduction was significant by nine
months from baseline 5.1 to 2.8 (3–6.3 and 1–3.8, respec-
tively; P = 0.0043). Within the Ice group, no changes in
pVAS were observed between any time points. Figure 2a
shows the change in pVAS during the nine month study
period. Variation in baseline pVAS was a consequence of
cases leaving the study before each time point.

Medication score

The medication score was used to determine whether
and to what extent the diets were able to reduce the
dependency on nondietary interventions in order to main-
tain an acceptable QoL. After three months, the median
drug score had decreased from 20 to 10 (ranges 10–30 at
baseline and 0–10 at three months; P = 0.058) for the Flame diet group. By contrast, in the Ice diet group
the median medication score remained the same
between baseline and three months at 25 (5–50 and 5–60,
respectively; NSD). After six months the medication
score showed a significant reduction in the Flame group
(median 20 versus 10, ranges 10–30 and 0–20; P = 0.021), which was maintained up to nine months (20
versus 5, ranges 10–30 and 0–20; P = 0.018). In addition,
the average medication scores at six and nine months
were significantly lower than those at one month
(P = 0.050 and P = 0.039, respectively). No significant
changes in scores were observed for the Ice diet group.
Figure 2. Standard boxplots (showing median with 25th to 75th percentiles) for clinical parameters assessed for two diet groups over the nine month feeding period.

Case numbers at each time point, Flame/Ice: time zero 21/19; three months 17/15; six months 12/12; nine months 14/7. Scores as a function of time and diet using: (a) Pruritus Visual Analog Score (pVAS); (b) medication; and (c) Canine Allergic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04).
between any of the time points. Figure 2b shows the medication score during the nine month study period.

**CADESI-04**

There was a reduction in median CADESI-04 score from 16 (10–59) at the beginning of the feeding period to 12 (2–36) after three months in the Flame diet group. The median score in the Flame group was 14.5 (4–73) at six months, and then 8 (4–40) after nine months. In the Ice group, the median CADESI-04 after three months of feeding decreased from 18 (6–69) to 13.5 (4–48), increasing to 21 (1–84) after six months, before dropping again to 15 (0–44) by the end of the study. None of these figures showed a significant change from baseline CADESI-04 values. Figure 2c shows CADESI-04 scores for both diet groups during the nine month study period.

**Score improvement**

At each time point the number of dogs showing a >30% and >50% improvement of the clinical scores were computed (Table 3). The analysis shows that for 11 of 11 data points (CADESI-04, pVAS and medication score combined) there was a larger proportion of cases that improved >30% in the Flame group than in the Ice group. This also was seen for nine of 11 of the data at the >50% threshold. Table 3 also illustrates that, in the Flame diet group, there was typically a progressive increase in the proportion of dogs showing >30% and >50% improvement over time. The pattern was not repeated in the Ice diet group.

**Return to normal**

Finally, it is of note that six dogs eventually achieved a normal score for the three parameters monitored in the Flame group, whereas just one dog attained this level of improvement in the Ice group.

**Dogs transferred to Pebble diet**

Owners elected to change the diet for six dogs. Data for these dogs were included in the analysis before but not after the change was performed. Dogs which transitioned to Pebble did not show a significant improvement: it should, however, be taken into account that four of these dogs were already on the same Flame diet and that, in the main study, it was shown that an improvement was present after three months. This suggests that stabilisation of the improvement could be expected, and was indeed the case for three of four dogs. One of the two dogs in the Ice diet group improved after switching to the Pebble diet.

**Palatability and digestive tolerance**

As mentioned in the Study population section above, one dog in each group refused the diet. Owners reported that the diets were well-accepted by all other dogs. In the Flame group, one dog developed chronic diarrhoea several weeks after the diet transition. This dog was removed from the study; causality was not established. In this group, one dog had very dry faeces (grade 5), 10 had grade 4 (optimal according to the scale used) and six had grade 3 faeces. In the Ice diet group, the stools were considered grade 5 in two dogs, while 14 had grade 4 and one grade 3 faeces.

**Discussion**

This study demonstrates that a commercially-prepared diet supplemented with a targeted mixture of antioxidants and with a modified fatty-acid composition reduces pruritus and has a drug-sparing effect on dogs with AD. There was modest itch improvement following one month of feeding the diet, although statistical significance was reached only after three months. The lesional scores showed improvement in both groups at certain times but statistical significance was not reached. This is probably because the study was somewhat underpowered for CADESI-04, accentuated by the fact that only moderate to mild cases were included, thereby reducing the scope for improvement of CADESI-04 score. The main purpose of the study was to achieve itch improvement with reduced requirement for medication, factors likely to positively impact the QoL of affected patients as well as their owners.14

The clearly illustrated drug-sparing effect also is of value because drugs used for the control of the clinical signs of cAD may be associated with adverse effects, compliance issues and, in some cases, considerable financial cost. The reduction of the medication score was evident after three months and became significant from six months onwards. It should be emphasized that AD is a life-long disease with early onset of clinical signs. In this regard, any safe, easy-to-use intervention capable of decreasing the dose or dose-duration of potentially problematic drugs is welcomed.

---

**Table 3.** Improvement of the clinical score for both diet groups: the percentage of cases at each assessment point which showed either a >30% or a >50% improvement in pruritus (Visual Analog Score, pVAS), Canine Allergic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) or medication score

|                  | Flame | One month | Three months | Six months | Nine months | Ice  | One month | Three months | Six months | Nine months |
|------------------|-------|-----------|--------------|------------|-------------|------|-----------|--------------|------------|-------------|---|
| **pVAS**         |       |           |              |            |             |      |           |              |            |             |   |
| >30%             | 47    | 82        | 46           | 64         |             |      |           |              |            |             |   |
| >50%             | 21    | 29        | 46           | 60         |             |      |           |              |            |             |   |
| **CADESI-04**    |       |           |              |            |             |      |           |              |            |             |   |
| >30%             | 44    | 42        | 72           | 55         |             |      |           |              |            |             |   |
| >50%             | 22    | 29        | 55           | 55         |             |      |           |              |            |             |   |
| **Medication**   |       |           |              |            |             |      |           |              |            |             |   |
| >30%             | 10    | 53        | 64           | 82         |             |      |           |              |            |             |   |
| >50%             | 5     | 29        | 36           | 73         |             |      |           |              |            |             |   |
| **pVAS**         |       |           |              |            |             |      |           |              |            |             |   |
| >30%             | 17    | 36        | 31           | 36         |             |      |           |              |            |             |   |
| >50%             | 0     | 21        | 8            | 18         |             |      |           |              |            |             |   |
| **CADESI-04**    |       |           |              |            |             |      |           |              |            |             |   |
| >30%             | 37    | 31        | 42           | 42         |             |      |           |              |            |             |   |
| >50%             | 25    | 23        | 25           | 25         |             |      |           |              |            |             |   |
| **Medication**   |       |           |              |            |             |      |           |              |            |             |   |
| >30%             | 6     | 7         | 8            | 18         |             |      |           |              |            |             |   |
| >50%             | 6     | 7         | 8            | 9          |             |      |           |              |            |             |   |
Both diets tested in this study were formulated to deliver high-quality maintenance nutrition and were comparable in all aspects apart from a small group of ingredients included in the Flame test diet to target mechanistic aspects of canine atopic dermatitis. Amongst these, vitamin E and lutein provide antioxidant benefits to the skin. In support of this activity, lutein has been found to concentrate in the skin following oral consumption in humans. The essential omega-6 polyunsaturated fatty acid linoleate is known to play a vital role in maintaining the structural integrity of the epidermal barrier, intrinsic as it is in the formation of certain ceramides. What is more, linoleic acid intake has been shown to influence aspects of integument performance as well as skin lipid composition in dogs. Taurine has been reported to contribute to keratinocyte hydration, thereby also contributing to barrier function. The theoretical immunomodulatory role of the test diet is provided by three components: omega-3 fatty acids, turmeric and licorice. Multiple studies have indicated a role for the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the management of canine skin inflammation. Turmeric is a source of phenolic compounds known as curcuminoids. These have significant anti-inflammatory capacity, particularly in relation to cell-mediated immunoreactivity. The incorporation of licorice root extract could provide an immunomodulatory benefit. A constituent of licorice, the triterpenoid saponin glycyrrhizin, has demonstrated the ability to suppress interleukin (IL)-4 levels and restore the immune balance of T helper (TH1/TH2) cells in a mouse allergy model. In addition, it was shown that glycyrrhizin attenuates B-cell production of allergen-specific immunoglobulin (IgE) and IgG1 and can act as a mast cell stabilizer. These are activities which have potential value to influence the immune dysregulation underlying cAD. In combination, this group of functional ingredients appears to have value in the management of disease symptoms.

Previous studies have indicated the value of a dietary approach to the management of canine allergic skin disease. Success with respect to food-derived allergies has been especially impressive. In cases where the allergy is at least partly environmentally derived, results have been more variable. A recent review elegantly summarises much of the work to date. A common issue highlighted is that many of the purported nutritional or nutraceutical-based therapeutics still lack efficacy data derived from well-designed, placebo-controlled studies.

There was excellent acceptance and digestive tolerance of the diets used in the study. The test diet was refused by only one dog and one other developed chronic diarrhoea, although no association between the diet and the gastrointestinal signs was established. There was some improvement in all scores in the group of dogs using the control diet, although statistical significance was not reached. The moderate improvement in the control group could have been a consequence of the benefits of providing high-quality nutrition to all participants.

It was notable that the main improvements in the test diet group were observed after three months. It is not surprising as other studies have shown that nutritional therapies can often take some time to build to maximal skin effects. Classical drug administration would consequently still be important during the early phase of dietary treatment in dogs suffering from severe AD. It is possible, however, that the diet alone may be sufficient to adequately control the clinical signs of atopic dogs with mild or moderate clinical signs. Further studies are needed to confirm this potential benefit. The results from this study were encouraging over the nine month duration. The number of cases lost before each time point was not ideal, reducing the number of cases completing the full study. What is more, it may have been valuable to increase the study period to establish whether the diet could maintain the reduced medication requirement for an extended period. A further limitation of the study was inclusion of mild and moderate cases only. It would have been interesting to see if the diet also could contribute to the management of severely atopic dogs.

Conclusion

In summary, to the best of the authors’ knowledge, this is the first time that a diet designed specifically to assist in the management of cAD has been shown to be efficacious in the framework of a double-blinded, placebo-controlled study. Importantly, it is seen that the QoL of atopic dogs could be improved using the dietary intervention and that the approach might mitigate against complications associated with drug therapy, providing significant benefit in a relatively short time frame.

Acknowledgements

We would like to thank the following people for their expert contribution to the study: Marie-Christine Cadiergues, Noëlle Cochet-Faire, Claudia Nett-Mettler, Didier Pin, Silvia Rüfenacht and Sébastien Viaud for clinical input, and Jeremy Laxalde for statistical guidance.

Author contributions

Adrian Watson: Conceptualization, Data curation, Funding acquisition, Methodology, Project administration, Resources, Validation, Writing-original draft, Writing-review & editing. Ana Rostaher: Data curation, Investigation, Methodology, Resources, Writing-review & editing. Nina Fischer: Data curation, Investigation, Methodology, Resources, Writing-review & editing. Claude Favrot: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing-original draft, Writing-review & editing.

References

1. Nuttall TJ, Marsella R, Rosenbaum MR et al. Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2019; 254: 1,291–1,300.
2. Olivry T, DeBoer DJ, Favrot C et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 2015; 11: 210.
3. Sharma S, Naura AS. Potential of phytochemicals as immune-regulatory compounds in atopic diseases: a review. Biochem Pharmacol 2020; 173: 113-790.
4. Magrone T, Jirillo E. Influence of polyphenols on allergic immune reactions: mechanisms of action. Prog Nutr Soc 2012; 71: 316–321.
5. Bensignor E, Morgan DM, Nuttall T. Efficacy of an essential fatty acid-enriched diet in managing canine atopic dermatitis: a randomized, single-blinded, cross-over study. Vet Dermatol 2008; 19: 156–162.
6. Plevnik Kapun A, Salobir J, Levart A et al. Vitamin E supplementation in canine atopic dermatitis: improvement of clinical signs and effects on oxidative stress markers. Vet Rec 2014; 175: 560.
7. Popa I, Watson AL, Solgadi A et al. Linoleate-enriched diet increases both linoleic acid esterified to omega hydroxy very long chain fatty acids and free ceramides of canine stratum corneum without effect on protein-bound ceramides and skin barrier function. Arch Dermatol Res 2018; 310: 579–589.
8. Olivry T, DeBoer DJ, Favrot C et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21: 233–248.
9. Witte-ROLLINS A, Murphy M, Becvarova I et al. Non-controlled, open-label clinical trial to assess the effectiveness of a dietetic food on pruritus and dermatologic scoring in atopic dogs. BMC Vet Res 2019; 15: 220.
10. Favrot C, Steffan J, Seewald W et al. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 2010; 21: 23–31.
11. Hill PB, Lau P, Rybnicek J. Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol 2007; 18: 301–308.
12. Fischer N, Tarpakati N, Leidi F et al. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol 2018; 29: 337–e118.
13. NRC (National Research Council) Energy. In: Nutrient Requirements of Dogs and Cats. The National Academies Press. Washington, D.C, USA: 2006; 22–48.
14. Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol 2010; 21: 456–462.
15. Roberts RL, Green J, Lewis B. Lutein and zeaxanthin in eye and skin health. Clin Dermatol 2009; 27: 195–201.
16. Obana A, Gohto Y, Nakazawa R et al. Effect of an antioxidant supplement containing high dose lutein and zeaxanthin on macular pigment and skin carotenoid levels. Sci Rep 2020; 10: 10,262.
17. Rabionet M, Gorgas K, Sandhoff R. Ceramide synthesis in the epidermis. Biochim Biophys Acta 2014; 1841: 422–434.
18. Marsh KA, Ruedisueli FL, Coe SL et al. Effects of zinc and linoleic acid supplementation on the skin and coat quality of dogs receiving a complete and balanced diet. Vet Dermatol 2000; 11: 277–284.
19. Janeke G, Sieffen W, Carstensen S et al. Role of taurine accumulation in keratinocyte hydration. J Invest Dermatol 2003; 121: 354–361.
20. Saevik BK, Bergvoll K, Holm BR et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol 2004; 15: 137–145.
21. Yadav VS, Mishra KP, Singh DP et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol 2005; 27: 485–497.
22. Han S, Sun L, He F et al. Anti-allergic activity of glycyrrhizic acid on lGf- mediated allergic reaction by regulation of allergy-related immune cells. Sci Rep 2017; 7: 7,222.
23. Olivry T, Bexley J, Mougeot I. Extensive protein hydrolyzation is indispensable to prevent lGf-mediated poultry allergen recognition in dogs and cats. BMC Vet Res 2017; 13: 251.
24. Bizikova P, Olivry T. A randomized, double-blinded crossover trial testing the benefit of two hydrolysed poultry-based commercial diets for dogs with spontaneous pruritic chicken allergy. Vet Dermatol 2016; 27: 289–e70.
25. Marchegiani A, Fruganti A, Spaterna A et al. Impact of nutritional supplementation on canine dermatological disorders. Vet Sci 2020; 7: 38.

Supporting Information
Additional Supporting Information may be found in the online version of this article.

Appendix 1: List of medications permitted for management of AD during the study

Résumé
Contexte – La dermatite atopique canine (cAD) est une dermatose prurigineuse récidivante chronique fréquente dont la gestion nécessaire souvent l’utilisation d’immunomodulateurs à vie. Un grand nombre de traitement est associé à des effets secondaires et complications potentielles dans leur utilisation au long cours.

Hypothèses – Le but de cette étude est de déterminer si un régime alimentaire complet et équilibré peut contribuer à la gestion de cAD. Nous supposons que l’alimentation pourrait réduire le prurit ainsi que le besoin de traitement au cours de la période de l’étude.

Sujets, matériels et méthodes – Quarante chiens de propriétaires, ayant eu un diagnostic détaillé de cAD, ont été répartis au hasard en deux groupes, chaque groupe ayant été nourri par une ou deux alimentations (test ou contrôle) pendant neuf mois. Nous déterminons le prurit, le CADESI-4 et le score médicamenteux, ce dernier reflétant les traitements nécessaires pour maintenir une qualité de vie satisfaisante pour l’animal.

Résultats – Les deux alimentations sont bien tolérées et acceptées. Il y avait une amélioration significative de score de prurit après trois mois de régime thérapeutique (P = 0.0001). Cette amélioration n’a pas été observée dans le groupe de chiens recevant le régime contrôle. Il y avait une diminution des besoins en traitement pour les chiens recevant le régime thérapeutique après trois mois (P = 0.058), et cette diminution était significative à six mois (P = 0.021) et neuf mois (P = 0.018). Aucune amélioration n’a été observée à aucun moment dans le groupe contrôle.

Conclusion – Les résultats suggèrent que le régime thérapeutique peut s’associer à la gestion de cAD en aidant à contrôler le prurit et diminuer le besoin de traitement.
Resumen
Introducción – la dermatitis atópica canina (cAD) es una enfermedad cutánea pruriginosa recidivante crónica común para la que el tratamiento suele depender del uso de fármacos inmunomoduladores durante toda la vida. Varios de los medicamentos utilizados están asociados con efectos adversos y la posibilidad de complicaciones durante el uso a largo plazo.

Hipótesis – el objetivo del estudio fue determinar si una dieta completa y equilibrada formulada para obtener un beneficio terapéutico podría contribuir al manejo de la cAD. Presumimos que la dieta reduciría el prurito y al mismo tiempo reduciría la necesidad de medicación durante el período de estudio.

Animales, materiales y métodos – Cuarenta perros de propietarios particulares tras haberse sometido a un estudio diagnóstico completo de cAD, fueron asignados aleatoriamente a dos grupos, cada grupo alimentado con una de las dos dietas (prueba o control) durante un máximo de nueve meses. Se evaluó el prurito, el índice de extensión y gravedad de la dermatitis atópica canina (cuarta revisión) y la puntuación de la medicación, esta última reflejando la medicación necesaria para mantener una calidad de vida satisfactoria para el animal.

Resultados – Ambas dietas fueron bien aceptadas y toleradas. Hubo una mejora significativa en la valoración de prurito después de tres meses de alimentar la dieta terapéutica (P = 0,0001). No se observó tal mejora en ningún momento en el grupo de perros que recibió la dieta de control. Hubo un requerimiento reducido de medicamentos para los perros que recibieron la dieta terapéutica después de tres meses (P = 0,058), y esa disminución fue significativa a los seis meses (P = 0,021) y nueve meses (P = 0,018). No se observó ninguna mejora en ningún momento en el grupo de control.

Conclusion – los resultados sugieren que una dieta terapéutica novedosa puede ayudar en el manejo de la cAD al ayudar a controlar el prurito y reducir la dependencia de la medicación.

Zusammenfassung
Hintergrund – Die atopische Dermatitis des Hundes (cAD) ist eine häufige wiederkehrende juckende Erkrankung, bei der ein Management häufig auf lebenslanger Verabreichung von immunmodulatorischen Medikamenten beruht. Eine Vielzahl der verwendeten Medikamente haben Nebenwirkungen und die Möglichkeit von Komplikationen, wenn sie langfristig eingesetzt werden.

Hypothesen – Das Ziel dieser Studie war es festzustellen, ob eine komplett und ausgewogene Ernährung, die zu therapeutischen Zwecken formuliert wurde, beim Management der cAD beitragen kann. Wir stellten die Hypothese auf, dass die Diät den Juckreiz reduzieren würde, während sie ebenso die Notwendigkeit einer Medikation während der Studienperiode reduzieren könnte.

Tiere, Materialien und Methoden – Vierzig Hunde im Privatbesitz, bei denen eine umfassende Diagnose von cAD gestellt wurde, wurden zufällig in zwei Gruppen eingeteilt; jeder Gruppe wurden bis zu neun Monate lang eine von zwei Diäten (Test oder Kontrolle) gewählt. Wir erfassen den Pruritus, den Canine Atopic Dermatitis Extent and Severity Index (4th Auflage) und die medizinische Bewertung, wobei letztere die Medikation reflektiert, die nötig ist, um eine zufriedenstellende Lebensqualität des Tieres zu erhalten.

Ergebnisse – Beide Diäten wurden gerne gefressen und gut toleriert. Nach drei Monaten der therapeutischen Nahrung bestand eine signifikante Verbesserung bei den Prurituswerten (P = 0,0001). Eine derartige Verbesserung wurde zu keinem Zeitpunkt bei der Hundegruppe beobachtet, welche die Kontrollgruppe gesehen.

Schlussfolgerungen – Die Ergebnisse zeigen, dass eine neuartige therapeutische Diät beim Management der cAD helfen kann, den Juckreiz zu kontrollieren und den Einsatz von Medikamenten zu reduzieren.
Nutritional management of canine atopic dermatitis

0.018) にも有意に見られた。対照群では、どの時点でも改善は見られなかった。

結論 - 今回の結果から、新しい治療法は、搔痒を抑え、薬への依存度を減らすことで、cADの管理を助けることが
できると考えられる。

摘要
背景 - 犬特应性皮炎(cAD)は一种常见的慢性复发性瘙痒性皮肤病，其治疗通常依赖于终生使用免疫调节
药物。使用的许多药物长期使用期间，可能存在不良反应和并发症。

假设 - 本研究的目的是确定为达到疗效而制定的完整和平衡的日粮是否有助于cAD管理，我们假设日粮将
减少瘙痒，同时也减少研究期间药物的需求。

动物、材料和方法 - 将40只私家犬(已接受CADD综合诊断)随机分配至两组，每组喂食两种日粮(试验或对照)
中的一种，持续长达9个月。我们评估了瘙痒、犬特应性皮炎程度和严重指数(第4版)和药物用量，后者对应
维持动物满意生活质量所需的药物。

结果 - 两种日粮均被广泛接受且耐受性。喂食日粮三个月后，瘙痒评分显著改善(P = 0.0001)。在给予对照饲
料的犬组中，在任何时间点均未观察到此类改善。3个月后，吃处方粮的犬的药物需求降低(P = 0.058)，并且
在第6个月(P = 0.021)和第9个月(P = 0.018)时降低显著。对照组在任何时间点均未观察到改善。

结论 - 结果表明，新处方粮可通过帮助控制瘙痒和减少对药物的依赖来帮助cAD的管理。

Resumo
Contexto – A dermatite atópica canina (DAC) é uma dermatopatia crônica pruriginosa e recidivante comum
para o animal. Ambas as dietas foram bem aceitas e toleradas. Houve uma melhora significativa no escore
de prurido após três meses consumindo a dieta terapêutica (P = 0,0001). Nenhuma melhora foi observada
em nenhum tempo experimental no grupo de cães tratados com a dieta controle. Observou-se uma
redução no requerimento de medicamentos nos cães que receberam a dieta terapêutica após três meses
(P = 0,058), e esta redução foi significativa após seis meses (P = 0,021) e nove meses (P = 0,018). Não foi
observada nenhuma melhora em nenhum tempo experimental no grupo controle.

Conclusões – Os resultados sugerem que a nova dieta terapêutica pode auxiliar no controle da DAC pela
redução do prurido e da dependência de medicação.